Protease inhibitors in liver disease

Area of Science:

• Hepatology
• Biochemistry
• Hematology

Background:

• Chronic liver diseases, including alcoholic cirrhosis and primary biliary cirrhosis, can affect liver function.
• Protease inhibitors play a crucial role in the hemostatic mechanism.
• Understanding the levels of these inhibitors in different liver disease types is important for assessing disease severity and complications.

Purpose of the Study:

• To measure and compare the levels of principal protease inhibitors in patients with alcoholic cirrhosis and primary biliary cirrhosis.
• To investigate the relationship between protease inhibitor levels and hepatocellular function.
• To determine the underlying cause of altered protease inhibitor levels in chronic liver disease.

Main Methods:

• Quantitative measurement of antithrombin III and alpha 2-antiplasmin levels.
• Clinical and biochemical assessment of hepatocellular function.
• Correlation analysis between protease inhibitor levels and serum albumin concentration.
• Screening for evidence of disseminated intravascular coagulation.

Main Results:

• Significantly reduced levels of antithrombin III and alpha 2-antiplasmin were observed in patients with alcoholic cirrhosis.
• Patients with primary biliary cirrhosis did not show reduced levels of these protease inhibitors.
• A significant positive correlation was found between the levels of both protease inhibitors and serum albumin concentration.
• No evidence of disseminated intravascular coagulation was detected in either patient group.

Conclusions:

• Impaired hepatic synthesis, rather than disseminated intravascular coagulation, is the likely cause of reduced antithrombin III and alpha 2-antiplasmin levels in alcoholic cirrhosis.
• Protease inhibitor levels can serve as indicators of hepatocellular dysfunction in chronic liver disease.
• Primary biliary cirrhosis, with preserved hepatocellular function, does not lead to a decrease in these specific protease inhibitors.